Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.

Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team..

Lancet HIV. 2017 May 8. pii: S2352-3018(17)30065-6. doi: 10.1016/S2352-3018(17)30065-6. [Epub ahead of print]

2.

Expression of p53 and HER2/Neu in Kenyan Women With Primary Ovarian Carcinoma.

Mutuiri AP, Nzioka A, Busarla SV, Sayed S, Moloo Z.

Int J Gynecol Pathol. 2016 Nov;35(6):537-543.

PMID:
26825003
3.

Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.

Arenas-Pinto A, Thompson J, Musoro G, Musana H, Lugemwa A, Kambugu A, Mweemba A, Atwongyeire D, Thomason MJ, Walker AS, Paton NI; EARNEST Trial Team..

J Neurovirol. 2016 Feb;22(1):104-13. doi: 10.1007/s13365-015-0374-7. Epub 2015 Aug 25.

PMID:
26323809
4.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team..

N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274.

5.

Wilms tumor survival in Kenya.

Axt J, Abdallah F, Axt M, Githanga J, Hansen E, Lessan J, Li M, Musimbi J, Mwachiro M, Newton M, Ndung'u J, Njuguna F, Nzioka A, Oruko O, Patel K, Tenge R, Ukoli F, White R, O'Neill JA Jr, Lovvorn HN 3rd.

J Pediatr Surg. 2013 Jun;48(6):1254-62. doi: 10.1016/j.jpedsurg.2013.03.021.

6.

Breast cancer diagnosis in a resource poor environment through a collaborative multidisciplinary approach: the Kenyan experience.

Sayed S, Moloo Z, Bird P, Wasike R, Njoroge W, Karanu J, Nzioka A, Sherman O, Prasad S, Mariwa C, Otieno JO, Chumba D, Koech D, Mbinga D, Mohammed M, Njoroge R, Chauhan R, Vinayak S, Kyobutungi C, Saleh M.

J Clin Pathol. 2013 Apr;66(4):307-11. doi: 10.1136/jclinpath-2012-201404. Epub 2013 Feb 1.

PMID:
23378268
7.
8.

Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.

Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team..

PLoS Med. 2012;9(6):e1001236. doi: 10.1371/journal.pmed.1001236. Epub 2012 Jun 12.

9.

Antiretroviral therapies in women after single-dose nevirapine exposure.

Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS; OCTANE A5208 Study Team..

N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.

Supplemental Content

Loading ...
Support Center